Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 8,625 matching trials from the live ClinicalTrials.gov search.
Conditions
Cytomegalovirus (CMV)-Positive Recipients, Allogeneic, Hematopoietic Cell Transplant (HCT)
Interventions
ASP0113, Placebo
Biological · Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
27
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 22 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 23 more
Conditions
Schizophrenia
Interventions
Aripiprazole IM Depot
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
96
States / cities
Chandler, Arizona • Anaheim, California • Cerritos, California + 78 more
Completed Phase 3 Interventional Results available

A Study in Moderate to Severe Rheumatoid Arthritis

NCT01710358
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Baricitinib, Methotrexate, Adalimumab Placebo, Baricitinib Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
45
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 39 more
Conditions
Breast Neoplasms
Interventions
Irinotecan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
57
States / cities
Mobile, Alabama • Anchorage, Alaska • Lewistown, Idaho + 39 more
Conditions
MSS, RAS-mutant Colorectal Cancer
Interventions
binimetinib, nivolumab, ipilimumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
33
States / cities
Los Angeles, California • Santa Monica, California • Newark, Delaware + 12 more
Conditions
Short Bowel Syndrome
Interventions
TED, SOC, Syringe, Needle
Drug · Other · Device
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 11 more
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Sirukumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
48
States / cities
Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 45 more
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Placebo, Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
57
States / cities
North Little Rock, Arkansas • Cerritos, California • Fountain Valley, California + 48 more
Conditions
Hemophilia A
Interventions
Antihemophilic factor, recombinant, manufactured protein-free
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 6 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
10
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Conditions
Diabetes Mellitus Type 2
Interventions
Insulin Lispro Protamine Suspension, Detemir
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Hueytown, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 24 more
Conditions
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Durvalumab, Laboratory Biomarker Analysis, Tremelimumab
Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1021
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 643 more
Conditions
Graft-vs-Host Disease
Interventions
Visilizumab
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
0 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
17
States / cities
Duarte, California • Stanford, California • Tampa, Florida + 13 more
Completed Phase 3 Interventional Results available

A Study in Second Line Metastatic Colorectal Cancer

NCT01183780
Conditions
Colorectal Cancer
Interventions
Ramucirumab, Placebo, Irinotecan, Folinic Acid, 5-Fluorouracil
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
92
States / cities
Sedona, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 89 more
Conditions
Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
Interventions
Tagraxofusp, Fludarabine, Cytarabine, Dexamethasone, Vincristine, Azacitidine, Methotrexate, Cytarabine IT, Hydrocortisone
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
29
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 25 more
Completed Not applicable Interventional Results available

Rheos® Pivotal Trial

NCT00442286
Conditions
Hypertension
Interventions
Rheos® Baroreflex Hypertension System
Device
Lead sponsor
CVRx, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
42
States / cities
Birmingham, Alabama • Inglewood, California • Los Angeles, California + 38 more
Conditions
Aneurysm, Brain
Interventions
WAVE, as part of the SMART COIL System
Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
34
States / cities
Dothan, Alabama • Tucson, Arizona • La Mesa, California + 29 more
Conditions
Leukemia
Interventions
filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
18 Months to 29 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
135
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 116 more
Conditions
Metastatic Breast Cancer
Interventions
Pegylated liposomal doxorubicin, Carboplatin, trastuzumab
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 51 more
Conditions
Prader-Willi Syndrome
Interventions
DCCR, Placebo for DCCR
Drug
Lead sponsor
Soleno Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
20
States / cities
Orange, California • Palo Alto, California • San Diego, California + 17 more
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
51
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 31 more
Conditions
Plaque Psoriasis
Interventions
NIS
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 100 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Rogers, Arkansas + 34 more
Conditions
Facial Paralysis
Interventions
NTX-001
Combination Product
Lead sponsor
Neuraptive Therapeutics Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Chicago, Illinois • Indianapolis, Indiana • St Louis, Missouri + 3 more
Conditions
Cutaneous Lupus Erythematosus (CLE)
Interventions
Edecesertib, Edecesertib Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • Fremont, California • Aurora, Colorado + 9 more